Boehringer is advancing the development of SZN-413 to prepare it for potential future clinical testingSZN-413 is a bi-specific antibody targeting ...

Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary ...

New research from the University of Dundee shows potential breakthrough for hard to treat cancers. Experts from the ...

Spherix Global Insights has provided a different angle on AbbVie’s successful retention of Humira sales in the face of ...

Insurance companies could be required to cover asthma inhalers at no cost in New York state. Assemblywoman Jessica ...

Insurance companies could be required to cover asthma inhalers at no cost in New York state. Assemblywoman Jessica ...

Potential launches from new challengers could start in 2026 with Boehringer Ingelheim and Zealand’s survodutide. Several ...

The 13 drugs most likely to be chosen for CMS negotiations, according to the study: Ozempic, Rybelsus and Wegovy (semaglutide): Novo Nordisk's treatment for Type 2 diabetes and weight management.

KRAS is the most mutated gene in cancer with mutations occurring in 17%–25% of all cancers, affecting millions of patients worldwide.

Experts have developed a breakthrough small-molecule drug, a 'protein degrader'. This molecule, called ACBI3, could potentially lead to new therapies independent of KRAS mutation type, improving ...

Experts from the University of of Dundee's Centre for Targeted Protein Degradation (CeTPD), working with Boehringer Ingelheim scientists, have developed a breakthrough small-molecule drug, a "protein ...

Spherix Global Insights compiled data from their RealTime Dynamix™ services in Crohn’s Disease, Rheumatoid Arthritis, and Psoriasis, fielded in late April 2024 (n=104 gastroenterologists, 103 ...